S Modvig1, M Degn2, B Sander3, H Horwitz4, B Wanscher5, F Sellebjerg6, J L Frederiksen7. 1. The MS Clinic, Department of neurology, Glostrup Hospital, University of Copenhagen, Denmark/Department of Clinical Immunology, Rigshospitalet, University of Copenhagen, Denmark signe.modvig.stausboell@regionh.dk. 2. The MS Clinic, Department of Neurology, Glostrup Hospital, University of Copenhagen, Denmark/Department of Diagnostics, Glostrup Hospital, University of Copenhagen, Denmark. 3. Department of Ophthalmology, Glostrup Hospital, University of Copenhagen, Denmark. 4. The MS Clinic, Department of Neurology, Glostrup Hospital, University of Copenhagen, Denmark/Department of Clinical Pharmacology, Bispebjerg Hospital, University of Copenhagen, Denmark. 5. Department of Clinical Neurophysiology, Glostrup Hospital, University of Copenhagen, Denmark. 6. Danish MS Research Centre, Department of Neurology, Rigshospitalet, University of Copenhagen, Denmark. 7. The MS Clinic, Department of Neurology, Glostrup Hospital, University of Copenhagen, Denmark.
Abstract
BACKGROUND: Optic neuritis is a good model for multiple sclerosis relapse, but currently no tests can accurately predict visual outcome. OBJECTIVE: The purpose of this study was to examine whether cerebrospinal fluid (CSF) biomarkers of tissue damage and remodelling (neurofilament light chain (NF-L), myelin basic protein, osteopontin and chitinase-3-like-1) predict visual outcome after optic neuritis. METHODS: We included 47 patients with optic neuritis as a first demyelinating episode. Patients underwent visual tests, optical coherence tomography (OCT), magnetic resonance imaging (MRI) and lumbar puncture. Biomarkers were measured in CSF by enzyme-linked immunosorbent assay (ELISA). Patients were followed up six months after onset and this included visual tests and OCT. Outcome measures were inter-ocular differences in low contrast visual acuity (LCVA), retinal nerve fibre layer (RNFL) and ganglion cell layer+inner plexiform layer (GC-IPL) thicknesses. RESULTS: CSF NF-L levels at onset predicted inter-ocular differences in follow-up LCVA (β=13.8, p=0.0008), RNFL (β=5.6, p=0.0004) and GC-IPL (β=4.0, p=0.0008). The acute-phase GC-IPL thickness also predicted follow-up LCVA (β=12.9, p=0.0021 for NF-L, β=-1.1, p=0.0150 for GC-IPL). Complete/incomplete remission was determined based on LCVA from 30 healthy controls. NF-L had a positive predictive value of 91% and an area under the curve (AUC) of 0.79 for incomplete remission. CONCLUSION: CSF NF-L is a promising biomarker of visual outcome after optic neuritis. This could aid neuroprotective/regenerative medical advancements.
BACKGROUND:Optic neuritis is a good model for multiple sclerosis relapse, but currently no tests can accurately predict visual outcome. OBJECTIVE: The purpose of this study was to examine whether cerebrospinal fluid (CSF) biomarkers of tissue damage and remodelling (neurofilament light chain (NF-L), myelin basic protein, osteopontin and chitinase-3-like-1) predict visual outcome after optic neuritis. METHODS: We included 47 patients with optic neuritis as a first demyelinating episode. Patients underwent visual tests, optical coherence tomography (OCT), magnetic resonance imaging (MRI) and lumbar puncture. Biomarkers were measured in CSF by enzyme-linked immunosorbent assay (ELISA). Patients were followed up six months after onset and this included visual tests and OCT. Outcome measures were inter-ocular differences in low contrast visual acuity (LCVA), retinal nerve fibre layer (RNFL) and ganglion cell layer+inner plexiform layer (GC-IPL) thicknesses. RESULTS: CSF NF-L levels at onset predicted inter-ocular differences in follow-up LCVA (β=13.8, p=0.0008), RNFL (β=5.6, p=0.0004) and GC-IPL (β=4.0, p=0.0008). The acute-phase GC-IPL thickness also predicted follow-up LCVA (β=12.9, p=0.0021 for NF-L, β=-1.1, p=0.0150 for GC-IPL). Complete/incomplete remission was determined based on LCVA from 30 healthy controls. NF-L had a positive predictive value of 91% and an area under the curve (AUC) of 0.79 for incomplete remission. CONCLUSION: CSF NF-L is a promising biomarker of visual outcome after optic neuritis. This could aid neuroprotective/regenerative medical advancements.
Authors: Helle H Nielsen; Catarina B Soares; Sofie S Høgedal; Jonna S Madsen; Rikke B Hansen; Alex A Christensen; Charlotte Madsen; Bettina H Clausen; Lars Henrik Frich; Matilda Degn; Christian Sibbersen; Kate L Lambertsen Journal: Front Neurol Date: 2020-06-11 Impact factor: 4.003
Authors: Manju L Subramanian; Viha Vig; Jaeyoon Chung; Marissa G Fiorello; Weiming Xia; Henrik Zetterberg; Kaj Blennow; Madeleine Zetterberg; Farah Shareef; Nicole H Siegel; Steven Ness; Gyungah R Jun; Thor D Stein Journal: Alzheimers Res Ther Date: 2020-09-17 Impact factor: 6.982
Authors: Caspar B Seitz; Falk Steffen; Muthuraman Muthuraman; Timo Uphaus; Julia Krämer; Sven G Meuth; Philipp Albrecht; Sergiu Groppa; Frauke Zipp; Stefan Bittner; Vinzenz Fleischer Journal: Ther Adv Neurol Disord Date: 2021-05-25 Impact factor: 6.570